

The Future of AI-Driven Remote Cardiac Monitoring


Proven effectiveness with unparalleled clinical results



 **implicit**[®]
SMART REMOTE MONITORING

An AI-Based Platform¹ for Improved Patient Care

The Implicitly cloud-based platform seamlessly aggregates and standardizes data from all cardiac implantable electronic device (CIED) manufacturers, making it accessible on a unified, user-friendly platform to facilitate interpretation. The exclusive CIED remote monitoring software, powered by FDA-cleared AI algorithms, delivers comprehensive patient data for enhanced cardiac care.



- **Unified Solution:** One login. One integrated platform. Efficiently streamline data from any CIED, anywhere, anytime.
- **Alert Prioritization:** Evolve from transmission-driven monitoring to efficient actionable alerts for prompt and critical patient care.
- **Data Revolution:** Leverage raw discrete data sourced directly from manufacturers. This raw data allows users to:
 - Engage with a consistent, sleek user interface, irrespective of the manufacturer.
 - Prioritize alert triage based on customizable clinic and patient settings.
 - Leverage data for research, avoiding the need for manual data extraction.
 - Export data for a variety of applications including performance analytics.
 - Optimize and streamline your billing workflows for enhanced efficiency and accuracy.

“Any transmission received on the manufacturer portal is automatically uploaded to the Implicitly platform, ensuring no data is missed.”

Jay Ganji, MD
Cardiologist
Piedmont Cardiovascular



¹ IM007; 2021. ILR ECG ANALYZER created by Implicitly is intended to be used by qualified healthcare professionals for the assessment of arrhythmias in Insertable Cardiac Monitor (ICM) ECG data. ILR ECG ANALYZER supports downloading and analyzing data recorded in compatible formats from ICMs. This version of the ILR ECG ANALYZER only supports ECG data from Medtronic ICMs. ILR ECG ANALYZER is intended to be electronically interfaced with other computer systems (remote monitoring platforms) that supply the ECG data to ILR ECG ANALYZER and receive the output of ILR ECG ANALYZER (analysis) for viewing by healthcare professionals. ILR ECG ANALYZER provides ECG signal processing and analysis, to detect asystole, bradycardia, atrial tachycardia or atrial fibrillation, ventricular tachycardia, normal rhythm and artifacts. ILR ECG ANALYZER is not for use in life supporting or sustaining systems or ECG monitor and Alarm devices. ILR ECG ANALYZER interpretation results are not intended to be the sole means of diagnosis. It is offered to physicians and clinicians on an advisory basis only in conjunction with the physician's knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. ILR ECG ANALYZER is interfaced with the compatible remote monitoring platform from which it receives compatible ICM data file input (Medtronic LNQT Medtronic REVEAL XT 9529 Medtronic REVEAL DX 9528) and to which it transmits the output. Read carefully all instructions before use. Results: sensitivity: 98.64 % (509/516), false positive rate: 24.03 % (68/283). FDA cleared Class II medical device and CE marked Class I medical device (under medical device directive 93/42). SignalHF is an FDA-cleared Class II medical device. Manufacturer: Implicitly. The SignalHF System is intended for use by qualified healthcare professionals (HCP) managing patients over 18 years old who are receiving physiological monitoring for Heart Failure surveillance and implanted with a compatible Cardiac Implantable Electronic Devices (CIED) (i.e., compatible pacemakers, ICDs, and CRTs). The SignalHF System provides additive information to use in conjunction with standard clinical evaluation. The SignalHF HF Score is intended to calculate the risk of HF for a patient in the next 30 days. This System is intended for adjunctive use with other physiological vital signs and patient symptoms and information and is not intended to independently direct therapy. See the instructions for use for more information.

Discover Our Unique Solution



Save time
by focusing
on meaningful
events

- Reduce false positives in Medtronic ILR ECG analysis by **79%** while keeping **99%** sensitivity² (*ILR ECG Analyzer*³)
- Reconnect **28%** of patients two days after they disconnect, using automated SMS⁴ (*Patient Connectivity Management*)
- Detect clinically relevant events, leading to **85%** fewer unnecessary AF alerts⁵ (*AF Alert Management*)
(And more thanks to *InLink*)



Improve patients
survival

- **26%** mortality reduction⁶
- **4%** decrease in hospitalization length⁶
(And more thanks to *SignalHF*⁷ and our *alert-based remote monitoring platform*)



Optimize billing
compliance and
maximize revenue

- Achieve **90%+** billing compliance with our dynamic billing engine⁸ (*Optimized scheduling and auto-generated reports*)

2. A. Rosier et al., "A novel machine learning algorithm has the potential to reduce by 1/3 the quantity of ILR episodes needing review", European Heart Journal, Volume 42, Issue Supplement_1, October 2021, ehab724.0316. 3. IM007: 2021. ILR ECG ANALYZER created by Implicitly is intended to be used by qualified healthcare professionals for the assessment of arrhythmias in Insertable Cardiac Monitor (ICM) ECG data. ILR ECG ANALYZER supports downloading and analyzing data recorded in compatible formats from ICMs. This version of the ILR ECG ANALYZER only supports ECG data from Medtronic ICMs. ILR ECG ANALYZER is intended to be electronically interfaced with other computer systems (remote monitoring platforms) that supply the ECG data to ILR ECG ANALYZER and receive the output of ILR ECG ANALYZER (analysis) for viewing by healthcare professionals. ILR ECG ANALYZER provides ECG signal processing and analysis, to detect asystole, bradycardia, atrial tachycardia or atrial fibrillation, ventricular tachycardia, normal rhythm and artifacts. ILR ECG ANALYZER is not for use in life supporting or sustaining systems or ECG monitor and Alarm devices. ILR ECG ANALYZER Interpretation results are not intended to be the sole means of diagnosis. It is offered to physicians and clinicians on an advisory basis only in conjunction with the physician's knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. ILR ECG ANALYZER is interfaced with the compatible remote monitoring platform from which it receives compatible ICM data file input (Medtronic LNQT1 Medtronic REVEAL XT 9529 Medtronic REVEAL DX 9528) and to which it transmits the output. Read carefully all instructions before use. Results: sensitivity: 98.64 % (509/516), false positive rate: 24.03 % (68/283). FDA cleared Class II medical device and CE marked Class I medical device (under medical device directive 93/42). 4. J. Durand et al., "Using technology to improve reconnection to remote monitoring in cardiac implantable electronic device patients", Cardiovascular Digital Health Journal, Volume 5, Issue 1, 2024, Pages 1-7, ISSN 2666-6936. 5. A. Lazarus et al., "Filtering of remote monitoring alerts transmitted by cardiac implantable electronic devices and reclassification of atrial fibrillation events by a new algorithm.", Cardiovascular Digital Health Journal 4.5 (2023): 149-154. 6. N. Varma et al., "Impact of a universal monitoring system (third party) on outcomes of ICD patients: A nationwide study", Heart Rhythm, 2024. 7. SignalHF is an FDA-cleared Class II medical device. Manufacturer: Implicitly. The SignalHF System is intended for use by qualified healthcare professionals (HCP) managing patients over 18 years old who are receiving physiological monitoring for Heart Failure surveillance and implanted with a compatible Cardiac Implantable Electronic Devices (CIED) (i.e., compatible pacemakers, ICDs, and CRTs). The SignalHF System provides additive information to use in conjunction with standard clinical evaluation. The SignalHF HF Score is intended to calculate the risk of HF for a patient in the next 30 days. This System is intended for adjunctive use with other physiological vital signs and patient symptoms and information and is not intended to independently direct therapy. See the instructions for use for more information. 8. Jay Ganji, MD, FACC, Cardiologist, Piedmont Cardiovascular, November 2022.

Customer Support by Experts

Our Customer Success team is your dedicated partner in ensuring unparalleled remote cardiac monitoring care. Ready to guide clinicians and staff, our team stands by to deliver exceptional customer service whenever you need it.

Comprehensive Support:

- Full onboarding and deployment support
- Guidance and best practice sharing
- Accessibility via phone, text, email, or chat
- Change management

Empower your team with the confidence of Implicity's Customer Success expertise.



EVIDENCE-RM Study: The Implicity Unparalleled Clinical Results



HRS/EHRA/APHRS/LAHRS Recommendations



About Implicity

Implicity is a global, digital MedTech software company that offers the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by Cardiac Electrophysiologist Arnaud Rosier, MD, PhD, the device-agnostic remote monitoring platform provides critical health information augmented by AI algorithms, enabling healthcare providers to make more informed decisions designed to improve patient outcomes.

<http://www.implicit.com>



North American Headquarters
185 Alewife Brook Parkway Suite 210
Cambridge, MA 02138, USA
contact@implicity.com

